NON-SMALL CELL LUNG CANCER

This pilot study tests whether it is safe and feasible to skip surgery in patients with stage II-III non-small cell lung cancer who have a complete response to chemotherapy and immunotherapy. Fourteen participants will be randomly assigned to either observation or standard surger…

This early-stage study tests a new gene-editing drug called EDB-102 in 15 adults with advanced non-small cell lung cancer that has spread to the liver and is no longer responding to standard targeted therapy. The drug uses CRISPR technology to seek out and disable a specific canc…

This study tests whether combining two drugs, SKB264 and anlotinib, can shrink tumors or slow disease in people with advanced non-small cell lung cancer that has spread to the liver and no longer responds to standard EGFR-targeted therapy. About 27 adults will receive the drugs o…

This study looks at whether giving a drug called leucogen along with the cancer pill pralsetinib can prevent low white blood cell counts in people with RET fusion-positive non-small cell lung cancer. About 25 people who have not had prior treatment will take part. The main goal i…

This study tests whether taking only a few lymph node samples (selective sampling) works as well as removing all nearby lymph nodes (systematic dissection) in people with stage IIA-IIIB non-small cell lung cancer. All participants will first receive chemotherapy combined with imm…

This study tests whether the drug divarasib can prevent lung cancer from coming back in people with a specific gene mutation (KRAS G12C) who have already had surgery and chemotherapy. About 400 adults with stage II-III non-small cell lung cancer will be randomly assigned to recei…

This early-phase study tests two drugs together—navlimetostat and pumitamig—in people with advanced non-small cell lung cancer that has a specific genetic change (MTAP-deficient). The main goal is to find a safe dose and see if the combination helps shrink tumors. About 17 adults…

This study tests a new drug called SYS6090, given together with chemotherapy or other targeted drugs, in people with advanced lung cancer that cannot be removed by surgery. The goal is to find safe doses and see if the combination can shrink tumors. About 596 adults with non-smal…

This study tests whether adding a new drug (BL-B01D1) to standard treatment (osimertinib) before and after surgery helps people with a specific type of lung cancer (EGFR-mutant). About 90 adults with early-stage, operable lung cancer will receive the combo or standard care. The m…

This study tests a new drug combination for people with advanced lung cancer that has a specific gene change (EGFR mutation). The experimental drug ANS014004 is designed to block a protein that often makes tumors stop responding to standard targeted therapy. The trial will first …

This study tests two drug combinations for people with a specific type of advanced lung cancer (EGFR-mutant NSCLC). One group gets a new drug (amivantamab) plus a targeted pill (lazertinib) as their first treatment. The other group gets amivantamab plus chemotherapy after their c…

This study tests a two-drug combination (ABSK043 and glecirasib) in 86 adults with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. The goal is to see if the combination is safe and shrinks tumors. Participants will take the drugs in 21-day cycles, and …

This study tests whether adding the experimental drug plinabulin to standard chemotherapy (docetaxel) helps people with advanced non-squamous lung cancer live longer. It includes about 442 adults whose cancer has worsened despite prior immunotherapy and platinum chemo. Participan…

This study tests a combination of two drugs (SHR-A1811 and pertuzumab) in people with advanced non-small cell lung cancer that has a specific genetic change called HER2. Participants must have already tried at least one other cancer treatment. The goal is to see if the combo can …

This phase 3 study tests whether a new drug (HS-20093) combined with an immunotherapy (adebrelimab) works better than the standard chemo (docetaxel) for people with advanced non-squamous non-small cell lung cancer that has no targetable genetic changes. About 450 adults who have …

This study tests whether giving sintilimab (an immunotherapy drug) together with chemotherapy can shrink advanced stage IIIC lung cancer enough to allow surgery. About 33 adults with previously untreated, unresectable non-small cell lung cancer will receive four cycles of the com…

This study tests whether giving fecal transplants from patients who responded well to immunotherapy can improve outcomes for people with stage II-III non-small cell lung cancer. About 68 participants will either receive standard treatment (chemotherapy plus durvalumab) or the sam…

This early-phase trial is for people with non-small cell lung cancer that has stopped responding to second-line treatment. Researchers will use a lab test on a patient's own tumor cells to pick the best chemotherapy drugs, then add the statin pitavastatin. The goal is to see if t…

This phase 3 study compares a new drug, YL202, with the standard chemotherapy docetaxel in adults aged 18–75 with advanced EGFR-mutant non-small cell lung cancer that has worsened after prior targeted therapy and chemotherapy. The main goals are to see if YL202 helps people live …

This early-phase study tests a personalized cell therapy (TCR1188-ABC) for people with advanced pancreatic, colorectal, lung, or bile duct cancers that have a specific KRAS G12V mutation. The treatment uses the patient's own immune cells, modified in a lab to better recognize and…

This study tests a new drug combination (SKB571) in 150 adults with non-small cell lung cancer. The goal is to see if the treatment shrinks tumors and how safe it is. Participants must have measurable tumors and be in good overall health.

This study tests two treatment plans for people with lung cancer that has spread to the brain but is not causing major symptoms. One group gets radiation to all brain tumors first, then a new immunotherapy drug (ivonescimab) plus chemo. The other group gets the drugs alone. The g…

This early-stage trial tests a new drug, AK138D1, alone or with another drug (ivonescimab) in people with advanced non-small cell lung cancer. The goal is to see if the treatment is safe and shrinks tumors. About 265 adults aged 18-75 with stage IIIB/IV cancer will take part.

This study tests a combination of two drugs, HLX43 and Serplulimab, in 120 adults with advanced lung cancer that has spread or cannot be removed. The goal is to see if the treatment shrinks tumors and how safe it is. Participants must have a specific type of lung cancer and meet …

This study tests a treatment made from a patient's own tumor-fighting immune cells (TILs) to see if it can shrink non-small cell lung cancer tumors. About 28 adults aged 18-70 with specific genetic types of lung cancer will receive their own lab-grown cells. The goal is to measur…

This phase 3 study tests whether adding a special type of radiation (SF-SBRT) to standard immunotherapy (toripalimab) and chemotherapy before surgery can improve outcomes for people with stage II-III non-small cell lung cancer. About 201 participants will be randomly assigned to …

This study tests whether adding a new drug (SYS6010) to standard treatment (osimertinib) before surgery can shrink tumors more effectively in people with a specific type of lung cancer (EGFR-mutant, non-squamous). About 120 adults with stage II to IIIB lung cancer that can be rem…

This study tests a new drug called JYP0322 against standard chemotherapy in people with a specific type of advanced lung cancer (ROS1-positive non-small cell lung cancer) that has stopped responding to previous targeted therapy. About 207 participants will be randomly assigned to…

This study tests a combination of two drugs, SHR-A1811 and ivonescimab, in 30 adults with advanced non-small cell lung cancer that has HER2 abnormalities. The goal is to see if the treatment can slow or stop cancer growth. Participants must have tried at least one prior therapy o…

This study tests whether giving the numbing drug lidocaine during lung cancer surgery can reduce the chance of the cancer returning or spreading. About 1,400 adults having minimally invasive lung cancer surgery will be randomly assigned to receive either lidocaine or a placebo. R…

This phase 2 trial tests two different immunotherapy drug combinations (durvalumab with monalizumab or oleclumab) followed by personalized radiation for people with advanced non-small cell lung cancer that has a high PD-L1 score. The goal is to see which combination works better …

This study tests a combination of two drugs (trastuzumab Rezetecan and ivonescimab) in 30 people with advanced non-small cell lung cancer that has HER2 gene changes. The goal is to see if the combination can shrink tumors or delay cancer growth. Participants must be 18-75, in goo…

This study tests an oral chemotherapy (paclitaxel) combined with immunotherapy given before surgery in patients aged 70-85 with non-small cell lung cancer. The goal is to see if this approach can shrink tumors enough to improve surgery outcomes and long-term survival. About 75 pa…

This early-phase study tests a new drug, ITC-6146RO, in about 100 adults with advanced or metastatic cancers (lung, breast, prostate, or other solid tumors) that have stopped responding to standard therapies. The trial has two parts: first, finding the safest dose, then expanding…

This study tests whether combining a targeted drug (furmonertinib) with local treatments like ablation or radiation can help control early-stage non-small cell lung cancer in people who cannot or choose not to have surgery. About 45 participants with specific EGFR gene mutations …

This study tests a combination of two drugs, chidamide and ivonescimab, for people with advanced non-small cell lung cancer that has stopped responding to immunotherapy and has a specific protein marker (YAP). The goal is to see if this new combo can control the cancer longer. Ab…

This early-phase study tests a new drug called QLS5316 in about 300 adults with advanced solid tumors (such as colorectal, stomach, head and neck, or lung cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, a…

This study tests whether a fecal microbiota transplant (FMT) — transferring healthy gut bacteria from a donor — can help the immune system fight advanced non-small cell lung cancer again in people whose cancer stopped responding to standard immunotherapy. About 15 adults will rec…

This early-phase study tests a combination of two drugs, izalontamab brengitecan and adagrasib, in 18 adults with advanced KRAS G12C-mutant non-small cell lung cancer that has not responded to other treatments. The main goal is to see if the combination is safe and works better t…

This study looks at whether removing the main lung tumor before taking the targeted drug osimertinib can help people with advanced EGFR-mutant non-small cell lung cancer live longer without the disease getting worse. About 118 adults with stage III-IV cancer who haven't had treat…

This study compares a new experimental drug, SYS6010, to a standard chemotherapy drug (docetaxel) in people with a specific type of advanced lung cancer (non-squamous non-small cell) that no longer responds to other treatments. The goal is to see if SYS6010 can help people live l…

This early-phase study tests a new daily pill, KQB368, in adults with advanced solid tumors (like lung, colon, or uterine cancer) that have a KRAS G12S or G12C mutation and no standard cure. The main goals are to find a safe dose and see if the drug can shrink tumors. About 48 pa…

This early-phase trial tests a new drug called HH160 in about 56 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. The study is open-label, meaning every…

This study tests whether adding targeted radiation to immunotherapy can help control advanced non-small cell lung cancer better than standard chemotherapy. It is for patients whose cancer has worsened after previous immunotherapy. About 39 adults will be randomly assigned to one …

This study tests a drug called AK112 in 60 adults with advanced non-squamous non-small cell lung cancer that has specific genetic changes. Participants must have already tried and failed a type of targeted therapy called a tyrosine kinase inhibitor (TKI). The goal is to see if AK…

This study tests whether adding a special type of radiation (quad shot radiotherapy) to a drug called QL1706 plus chemotherapy can better control advanced non-small cell lung cancer. QL1706 is an antibody that helps the immune system fight cancer. The trial will include 104 peopl…

This early-phase trial tests an experimental drug called FXB0871 in about 138 adults with advanced solid tumors, including non-small cell lung cancer and liver cancer, that have stopped responding to standard treatments. The study has two parts: first, finding a safe dose, and se…

This study looks at whether surgically removing the main lung tumor before giving immunotherapy (sintilimab) and chemotherapy can help people with advanced non-small cell lung cancer live longer without the disease getting worse. About 118 adults aged 18-75 with a specific type o…

This early-stage study tests a new drug called CS08399 in adults with advanced solid tumors or lymphoma that have a specific gene deletion (MTAP). The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 186 people will take part.

This study tests a new treatment called Y-90 FAPI for people with advanced non-small cell lung cancer that has stopped responding to standard therapies. The treatment delivers radiation directly to cancer cells by targeting a protein found on tumor-supporting cells. The goal is t…

This early-phase trial tests the safety of a new drug, IM-1617, in about 175 adults with advanced solid tumors (colorectal, lung, breast, stomach, esophageal, or other cancers that have spread or can't be removed by surgery). The study first finds a safe dose, then checks how wel…

This study tests a combination of the targeted drug limertinib plus chemotherapy (carboplatin and etoposide) in people with a specific type of lung cancer (EGFR-mutant NSCLC) that has transformed into small cell lung cancer after initial targeted therapy stopped working. About 30…

This study tests whether adding a new drug (recaticimab) to standard immunotherapy and chemotherapy before surgery can improve outcomes for people with resectable non-small cell lung cancer. About 78 adults with stage II to IIIB cancer will receive the combination, then have surg…

This study tests whether a new MRI contrast agent, gadopiclenol, can detect brain metastases earlier than standard methods in 180 patients with advanced lung, breast, or skin cancer. Early detection may offer more treatment options and prevent neurological symptoms. Participants …

This early-phase study tests a new radioactive antibody (NTH-2403) that targets a protein found on certain cancer cells. The goal is to see if it is safe and can help doctors see tumors more clearly using imaging. About 16 adults with advanced colorectal, head and neck, lung, or …

This study looks at whether low-dose CT scans can help find lung cancer early in people aged 40 to 80 who have never smoked. About 2,500 participants will fill out questionnaires, give blood and urine samples, and have lung function tests and CT scans. Researchers will track how …

This study looks at whether a two-week program of walking and breathing exercises before surgery can help people with non-small cell lung cancer feel less pain, recover faster, and leave the hospital sooner. About 62 adults scheduled for lung cancer surgery will be split into two…

This study tests whether adding pentoxifylline and vitamin E to standard chemoradiation can prevent lung injury (pneumonitis) in 150 adults with stage III non-small cell lung cancer. The goal is to reduce side effects and improve quality of life. Participants will take the study …

This study tests a smart breathing exercise device for people recovering from lung cancer surgery. About 200 adults will either use the device for 30 days after surgery or receive standard care. The goal is to see if the device improves lung function, reduces shortness of breath,…

This study tests a LINE chatbot that gives visual, interactive tips to help lung cancer patients manage side effects from their targeted therapy. About 178 people with advanced lung cancer will either get usual care or also access to the chatbot. The goal is to see if the chatbot…

This study tests whether adding megestrol acetate (a drug that stimulates appetite) to standard cancer therapy helps malnourished patients with non-small cell lung cancer gain weight. About 116 adults with advanced lung cancer will be randomly assigned to receive either standard …

This study tests a new way to perform lung cancer surgery for people with early-stage non-small cell lung cancer. Surgeons will use 3D virtual reality models and a special dye to see exactly which part of the lung needs to be removed. The goal is to make the operation more succes…

This pilot study tests whether a personalized exercise program is practical for people with stage II or III lung cancer. About 20 participants will follow the program before and after their cancer treatment. The main goal is to see if they can attend at least 80% of the exercise …

This study looks at whether adding electro-acupuncture to standard immunotherapy and chemotherapy can help people with advanced non-small cell lung cancer live longer without their disease getting worse. About 424 participants will receive either real or sham acupuncture alongsid…

This study looks at how the immune system responds to immunotherapy in people with early-stage solid cancers like lung, head and neck, melanoma, and bladder cancer. Researchers will collect blood and tumor samples from 600 participants before and after treatment to find biologica…

This study will follow about 300 people with advanced solid tumors (like lung or stomach cancer) who are getting adebrelimab as part of their treatment. Researchers want to see how safe and effective this drug combination is in real-world settings, not just in strict clinical tri…

This study watches how well the drug repotrectinib works and what side effects it causes in Korean patients with a specific type of lung cancer or solid tumors that have certain gene changes. About 10 patients will be followed for up to 12 months during their normal treatment. Th…

This study talks to about 85 lung cancer patients and 15 doctors in China to find out what makes it hard or easy to keep taking the drug osimertinib after surgery. The goal is to learn about side effects, costs, support, and communication issues so that future patients can stay o…

This study looks at whether getting immunotherapy in the morning versus the afternoon changes how well it works for people with advanced lung cancer or head and neck cancer. About 238 participants will be randomly assigned to morning or afternoon infusions. Researchers will track…

This study will look at 1000 people with a type of lung cancer that has not been treated yet. Doctors want to see how well different genetic tests agree with each other when looking for a specific change in the cancer cells. The goal is to make sure patients get the right test to…

This study aims to see if changes in certain immune cells in the blood can predict how well advanced lung cancer patients respond to a combination of chemotherapy and immunotherapy. About 80 adults with stage IIIB or IV non-small cell lung cancer will give blood samples before an…

This study will collect tumor samples from 150 adults with non-small cell lung cancer (stages I to IV) to learn why the cancer grows, spreads, or returns after treatment. Researchers will analyze the genes, metabolism, and immune cells in the tumors and link these findings to pat…

This study looks at whether tiny particles in the blood, called extracellular vesicles, can help doctors predict if immunotherapy will work for people with advanced lung cancer or melanoma. Researchers will collect blood samples from 378 patients before and during standard treatm…

This early study tests whether applying low-intensity electric fields (TTFields) to the chest before lung cancer surgery is safe and affects cancer-related genes. About 18 adults with stage I-IIIA non-small cell lung cancer will wear a non-invasive device for a short time before …

This study will check if 3D models made from CT scans without contrast dye are as accurate as regular 2D CT scans with dye for planning minimally invasive lung cancer surgery. About 50 adults with early-stage lung cancer will take part. The goal is to see if the 3D method can rel…

This study looks at whether a blood test can find tiny bits of cancer DNA left after surgery in people with breast, lung, prostate, ovarian, or stomach cancer. About 840 adults who had their cancer removed will give blood samples over a year to see if the DNA comes back. The goal…

This study tests whether a special headset (extended reality, or XR) can help surgeons better plan the removal of cancerous lymph nodes in the neck for people with lung cancer. Ten participants will have their PET and CT scans combined into a 3D model that the surgeon views throu…

This study involves 3,400 people with advanced non-small cell lung cancer to see if a new test for a protein called TROP2 works consistently across different laboratories. The goal is to ensure that doctors can reliably use this test to guide treatment decisions. Participants pro…

This study will compare an intelligent pulmonary function exercise device with usual care and natural recovery in patients recovering from lung cancer surgery. After lung cancer surgery, many patients have reduced lung function, shortness of breath, lower exercise tolerance, and…